Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director John Mendlein sold 1,364 shares of the firm’s stock in a transaction that occurred on Friday, June 3rd. The stock was sold at an average price of $22.79, for a total value of $31,085.56. Following the sale, the director now directly owns 158,091 shares of the company’s […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) has been assigned an average rating of “Buy” from the twelve analysts that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating on the company. […]
Wall Street brokerages predict that Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) will announce earnings of ($0.86) per share for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for Fate Therapeutics’ earnings, with estimates ranging from ($1.00) to ($0.73). Fate Therapeutics reported earnings per share of ($0.58) during the same quarter last […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have earned an average rating of “Buy” from the twelve ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have earned an average rating of “Buy” from the twelve research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eight have assigned a buy recommendation to the […]